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Objective. To determine the significance of anti-U1 ribonucleoprotein (RNP) 
antibodies (Abs) in cerebrospinal fluid (CSF) from systemic lupus erythematosus (SLE) and 
mixed connective tissue disease (MCTD) patients with central neuropsychiatric (NP) SLE.  
Methods. Antinuclear Abs including anti-U1RNP Abs were determined in sera and 
CSF of 24 patients with SLE and four patients with MCTD and central NPSLE using an 
RNA immunoprecipitation assay and ELISA. The frequency of CSF anti-U1RNP Abs in 
patients with central NPSLE was examined, and the anti-U1RNP index (= [CSF anti-U1RNP 
Abs /serum anti-U1RNP Abs] / [CSF IgG /serum IgG]) was compared with CSF interleukin 
(IL)-6 levels and the albumin quotient (Qalb, an indicator of blood brain barrier damage). 
CSF and serum Abs against U1-70K, A, and C including autoantigenic regions were 
examined, and the anti-70K, A, and C indices as well as the anti-U1RNP index were 
calculated.   
Results. CSF anti-U1RNP Abs with an increased anti-U1RNP index showed 64% 
sensitivity and 93% specificity for central NPSLE. The anti-U1RNP index did not correlate 
with CSF IL-6 levels or Qalb. The anti-70K index was higher than the anti-A and C indices 
in CSF of anti-U1RNP Ab-positive patients with central NPSLE. The major autoantigenic 
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region for CSF anti-70K Abs appeared to be localized in the U1-70K 141–164 amino acid 
residues within the RNA-binding domain.  
Conclusions. CSF anti-U1RNP Abs and the anti-U1RNP index are useful indicators 
for central NPSLE in anti-U1RNP Ab-positive patients. The predominance of anti-70K Abs 
in CSF suggests intrathecal anti-U1RNP Ab production.  
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Systemic lupus erythematosus (SLE) is a chronic, remitting and relapsing, 
multisystem autoimmune disease that predominantly affects women. Among various organ 
damages, neuropsychiatric SLE involving the central nervous system (CNS; central NPSLE) 
is a life-threatening severe manifestation. The overall prevalence of NPSLE varies between 
14 and 75% in a representative selection of studies using the American College of 
Rheumatology (ACR) nomenclature (1). In fact, NPSLE may affect mortality in SLE and is 
associated with a significant negative impact on a patients’ quality of life. However, 41% of 
all CNS manifestations in SLE patients may be attributed to factors other than lupus (2).  
Although the pathophysiology of most NPSLE cases is not well determined, a 
particular subset of autoantibodies (Abs) is associated with neuronal injury. A subset of 
anti-DNA Abs cross-reacts with a sequence within the N-methyl-D-aspartate receptor subunit 
NR2 (anti-NR2 Abs), causing excitatory synaptic transmission in the CNS (3). Anti-NR2 
Abs preferentially target the hippocampus, suggesting that anti-NR2 Abs may disrupt normal 
cognitive processes (4). However, serum anti-NR2 Abs may be associated with depressive 
mood (5), but not cognitive dysfunction (5, 6). Arinuma et al. (7) reported that anti-NR2 Abs 
in cerebrospinal fluid (CSF), but not in serum, were involved in diffuse central NPSLE. 
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Anti-ribosomal P Abs have been reported as neurotoxic autoAbs (8–10). Abnormal behavior 
can be induced in normal mice by administering anti-ribosomal P Abs (10), although serum 
anti-ribosomal P Abs are not specific to human central NPSLE (11). In association with 
thrombosis, anti-β2-glycoprotein I and prothrombin Abs are recognized as pathogenic Abs in 
focal central NPSLE such as cerebrovascular disease (12).  
In addition to autoAbs, several proinflammatory cytokines and chemokines have 
been detected in serum and CSF of patients with SLE. The most important cytokine in SLE 
and NPSLE may be interferon (IFN)-α (13–15). A recent report showed the presence of 
IFN-α, IFN-γ-inducible protein 10 (IP-10), interleukin (IL)-8, and monocyte chemotactic 
protein (MCP)-1 in the CSF from patients with NPSLE (15). IFN-α generation in SLE is 
caused, at least partially, by autoAbs that bind to ribonucleoprotein (RNP) particles released 
from dead and dying cells. Santer et al. clearly suggested that IFN-inducing activity in CSF 
correlates with serum anti-U1RNP Abs, but not with other known antinuclear antibodies 
(ANA) (15). Therefore, anti-U1RNP Abs and their immune complex in CSF may have 
pathogenic roles in central NPSLE. Okada et al. reported 14 patients with aseptic meningitis 
(eight with SLE, six with mixed connective tissue disease [MCTD] or undifferentiated 
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connective tissue disease, and one with Sjögren’s syndrome) among 1560 patients with 
connective tissue disease. Serum anti-U1RNP Abs were positive in 13 of the 14 patients with 
aseptic meningitis, suggesting that anti-U1RNP Abs may be linked to central NP 
manifestations (16). In the present study, we evaluated the clinical significance and 
immunological characteristics of anti-U1RNP Abs in CSF derived from SLE and MCTD 
patients with central NP manifestations.  
 
PATIENTS AND METHODS 
Patients. Patients with SLE or MCTD who revealed CNS manifestations and had 
been admitted to the Department of Rheumatology and Clinical Immunology, Kyoto 
University Hospital, from March 2002 to October 2007 were enrolled. SLE was diagnosed 
according to the ACR criteria (17, 18) and MCTD was diagnosed according to the criteria 
proposed by the Ministry of Health and Welfare in Japan (19). CNS manifestations were 
classified according to the case definitions for NP syndromes in SLE (20). Evaluation of NP 
syndromes included neuropsychiatric testing and magnetic resonance imaging (MRI) of the 
brain. Patients were diagnosed with central NPSLE retrospectively, according to 
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Kwiecinski’s criteria (21) with some modifications. Briefly, central NPSLE was defined as 
the presence of at least two of the following six items: 1) recent-onset of psychosis, 2) 
transverse myelitis, 3) aseptic meningitis, 4) seizures, 5) pathologic changes visualized on 
brain MRI, and 6) severely abnormal cognitive dysfunction documented by neuropsychiatric 
testing. Oligoclonal IgG bands in the CSF were not included, and CNS manifestations 
caused by other factors (e.g., concurrent non-SLE NP disease such as infection and 
secondary NPSLE such as uremia, hypertension, and complications of SLE therapy) were 
not defined as central NPSLE. In the present study, small punctate focal lesions in white 
matter, cortical atrophy, periventricular white matter hyperintensity, diffuse white matter 
changes, discrete gray matter lesions, diffuse gray matter hyperintensities, cerebral edema, 
and new infarct were considered as pathologic changes on brain MRI. The present study was 
conducted in compliance with the Declaration of Helsinki and approved by the Kyoto 
University Ethics Committee Review Board (approval #E97).  
Samples.  After an acute phase of massive cerebrovascular disease (CVD) was 
ruled out by brain MRI screening, CSF was taken from patients within 3 days from the onset 
of CNS manifestations. We have a written informed consent from all of the studied patients. 
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Serum samples were collected from all patients on the same day, and both samples were 
stored at -80°C. Routine CSF and serum analyses, including total protein, albumin, and IgG 
level, were conducted. CSF interleukin (IL)-6 (R&D Systems, Minneapolis, MN, USA) and 
interferon (IFN)-α (Bender MedSystems, Vienna, Austria) levels were determined by ELISA, 
according to the manufacturer’s protocol. The sensitivity of the IFN-α assay was more than 
5 pg/mL. 
Qalb and IgG index. To determine blood brain barrier (BBB) damage, the albumin 
quotient (Qalb, normal < 0.0076) was calculated as the ratio of CSF albumin (mg/dL) to 
serum albumin (mg/dL) (22). The IgG index was calculated as the IgG ratio (CSF IgG 
concentration [mg/dL] /serum IgG concentration [mg/dL])/Qalb.  
Detection of antinuclear antibodies (ANA) in sera and CSF by RNA 
immunoprecipitation. RNA immunoprecipitation (RNA-IPP) using HeLa cell extracts was 
performed to determine anti-RNA-associated antigen Abs, such as anti-U1RNP, Sm, 
SS-A/Ro (SSA), SS-B/La (SSB), and ribosomal P Abs in sera and CSF (23). A 10 µl sample 
of sera or CSF was mixed with 2 mg of protein A SepharoseTM CL-4B (GE Healthcare, 
Upsala, Sweden) in 500 µl of IPP buffer (10 mM Tris-HCl at pH 8.0, 500 mM NaCl, 0.1% 
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Nonidet P-40 [NP-40]) and incubated on a rotator for 2 h at 4°C. The IgG-coated Sepharose 
was washed four times in 500 µl of IPP buffer using 10-s spins in a microfuge and 
resuspended in 400 µl of NET-2 buffer (50 mM Tris-HCl at pH 7.5, 150 mM NaCl, 0.05% 
NP-40). For RNA analysis, this suspension was incubated with 300 µl of HeLa cell extracts, 
derived from 6 × 106 cells, on a rotator for 2 h at 4°C. The antigen-bound Sepharose was 
then collected by a 10-s centrifugation in a microfuge, washed four times with 500 µl of 
NET-2 buffer, and resuspended in 270 ml of NET-2 buffer. To extract bound RNAs, 30 µl of 
3.0 M sodium acetate, 15 µl of 20% sodium dodecyl sulfate, and 300 µl of 
phenol/chloroform/isoamyl alcohol (50:50:1; containing 0.2 g of 8-hydroxyquinoline and 40 
ml of 0.1 M Tris-HCl at pH 7.5) were added to the Sepharose beads. After agitation in a 
vortex mixer and spinning for 1 min, RNAs were recovered in the aqueous phase after 
ethanol precipitation and dissolved in 20 µl of electrophoresis sample buffer composed of 10 
M urea, 0.025% bromphenol blue, and 0.02 % xylene cyanol FF (Bio-Rad, Hercules, CA, 
USA) in Tris-borate-EDTA buffer (90 mM Tris HCl at pH 8.6, 90 mM boric acid, and 1 mM 
EDTA). The RNA samples were denatured at 65°C for 5 min and then resolved by 7 M 
urea-10% polyacrylamide gel electrophoresis with silver staining (Bio-Rad). Anti-U1RNP, 
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Sm, SSA, and SSB Abs were determined as positive when U1RNA, U1-U6RNA, SSA-RNA 
(Y1-Y5RNA), and SSB-RNA (5S-ribosomal RNA, 7S-RNA, and Y1-Y5RNA) were 
precipitated, respectively.  
Detection of ANA in sera and CSF by ELISA. Serum anti-U1RNP, dsDNA, SSA, 
and ribosomal P Abs were also determined by ELISA using recombinant U1RNP 
(Mesacup®-2 test RNP, Medical and Biological Laboratories [MBL] Co., Nagoya, Japan), 
purified dsDNA (Mesacup DNA-II t st ds®, MBL Co.), recombinant SS-A (Mesacup®-2 test 
SS-A, MBL Co.), and recombinant ribosomal P proteins (Ribosomal P ELISA kit, MBL Co.), 
according to the manufacturer’s protocol. Anti-ribosomal P and dsDNA Abs in CSF were 
determined to be positive when the experimental titer was more than that of the mean + 2SD 
of 10 negative controls. CSF samples derived from patients with other autoimmuine diseases 
(4 with polyarteritis nodosa, 4 with multiple sclerosis, and 2 with rheumatoid arthritis) were 
used as negative CSF controls for the anti-ribosomal P and dsDNA Abs. These patients had 
CNS manifestation and/or CSF abnormality, but not NPSLE, and negative results for their 
serum ANA were confirmed. Sera were diluted 1:100, and CSF samples were diluted 1:5 
using phosphate buffer saline (PBS). To determine the levels of anti-70K, A, and C Abs, 
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recombinant U1-70K, A, and C (MBL Co.) along with coating buffer (pH 9.4) (1 µg/mL) 
were bound to ELISA plates, and the wells were blocked using 5% bovine serum albumin 
(BSA) in PBS. Patient sera and CSF containing anti-U1RNP Abs were added and incubated 
at room temperature for 2 h, followed by detection of bound IgG with alkaline 
phosphatase-conjugated anti-human IgG (Southern Biotechnology Associates Inc., 
Birmingham, AL, USA) at OD405 nm in a microtiter ELISA reader. All assays were performed 
in triplicate. We confirmed that the OD405nm values of the CSF-experimental wells were 
included within the linear range of the positive control. If a 1:5 dilution was not appropriate, 
the dilution was changed in such samples and the obtained titer was adjusted. 
Anti-U1RNP ratio and anti-U1RNP index. Arbitrary units of the anti-U1RNP Abs 
in each sample were determined using serum and CSF anti-U1RNP Ab-positive (defined as 
100 units) and negative standard samples. More precisely, the arbitrary units for serum or 
CSF anti-U1RNP Abs were calculated as: ([OD405 nm of experimental well − OD405 nm of 
anti-U1RNP Ab-negative standard well] × 100/[OD405 nm of anti-U1RNP Ab-positive 
standard well − OD405 nm of anti-U1RNP Ab-negative standard well]). After obtaining the 
arbitrary units of the anti-U1RNP Ab, the anti-U1RNP ratio and anti-U1RNP index were 
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calculated as: (CSF arbitrary anti-U1RNP Ab units × 5/serum arbitrary anti-U1RNP Ab units 
× 100) and anti-U1RNP ratio/IgG ratio, respectively. The difference in the dilutions between 
serum (×100) and CSF (×5) was adjusted, and the anti-70K, A, and C indices were obtained 
by the same calculation method.  
Determination of autoantigenic regions recognized by serum and CSF anti-70K 
Abs. To compare the autoantigenic regions in the U1-70K proteins recognized by the CSF 
and serum anti-U1RNP Abs, we prepared 22 overlapping synthetic peptides (17–24 amino 
acids [aa]) identical with the U1-70K partial sequences (24) (Fig. 4). Synthetic peptides (100 
µg/ml) with coating buffer (pH 9.4) were bound to ELISA plates and the wells were blocked 
with 5% BSA in PBS. Sera and CSF from eight patients with central NPSLE were diluted to 
100 µg/mL with PBS and then incubated for 2 h at room temperature, followed by detection 
of bound IgG with alkaline phosphatase-conjugated anti-human IgG (Southern 
Biotechnology Associates Inc.) at OD405 nm in a microtiter ELISA reader. All assays were 
performed in triplicate. Positivity was determined as more than the mean + 2SD of the 
negative control samples obtained from patients without serum and CSF anti-U1RNP Abs. 
Statistical analysis. Differences in the frequencies of ANA in CSF and serum were 
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evaluated by the chi-square (χ2) test and Fisher’s exact test as appropriate. The Student’s 
t-test was used to compare the difference between two group means. Pearson’s product 
moment correlation coefficients (r) were calculated to evaluate the correlation between the 




Patient characteristics. NP syndromes were detected in 24 patients with SLE and 
four patients with MCTD. All patients were female, and their age at onset of CNS 
manifestations was 34.1 years (range, 19–58 years). According to the ACR nomenclature 
(20), the symptoms of central NPSLE exhibited by our patients were as follows: headache, 
cerebrovascular disease, cognitive dysfunction, seizures and seizure disorder, aseptic 
meningitis, psychosis, acute confusional state, demyelinating syndrome, anxiety disorder, 
and movement disorder.  
CSF findings and ANA profiles in patients with central NPSLE. Fourteen patients 
were diagnosed with central NPSLE (Table 1). All patients except for patient 11 needed a 
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high-dose corticosteroid treatment along with methylprednisolone pulse therapy and/or 
immunosuppressive agents for their central NPSLE. Aseptic meningitis most frequently 
occurred (five patients). Of the 14 patients, the cell number in CSF increased in six patients 
(46%, normal < 4 cells/µl), and total protein concentration increased in eight patients (57%, 
normal < 40 mg/dL). CSF IL-6 was elevated in five of 12 patients (42%, normal < 4.3 pg/mL 
[25]), and the IgG index increased in nine of 14 (64%, normal < 0.67). Qalb, an index of 
blood brain barrier (BBB) permeability, increased in eight of 14 patients (57%, normal < 
0.0076 [22]). By RNA-IPP, anti-U1RNP, SSA, SSB, and Sm Abs were detected in sera from 
11 (79%), eight (57%), one (7%), and four (29%) patients, respectively. Anti-ribosomal P 
and dsDNA Abs were determined as positive by ELISA in sera from four (29%) and six 
(43%) patients, respectively. In contrast, anti-U1RNP Abs in CSF were most frequently 
detected by RNA-IPP (82%) in CSF from anti-U1RNP Ab-positive patients with central 
NPSLE (Fig. 1 and 2A). The anti-U1RNP ratios increased more than the IgG ratios in 
patients with CSF-anti-U1RNP Abs (Fig. 2B). CSF anti-SSA and dsDNA Abs were detected 
in only three and one patient, respectively. Anti-ribosomal P and Sm Abs were absent in CSF.  
CSF findings and ANA profiles in patients without central NPSLE. CNS 
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manifestations were diagnosed in 14 patients as concurrent non-SLE central NP diseases or 
secondary central NP syndromes (Table 2). Increased cell number and protein concentrations 
were observed in three (21%) and five (36%) patients, respectively. IL-6, the IgG index, and 
Qalb were elevated in four (40%), seven (54%), and two (15%) out of 14 patients, 
respectively. These values were not significantly different between patients with and without 
central NPSLE. In contrast to central NPSLE, CSF anti-U1RNP Abs were detected in only 
one patient (#15) without central NPSLE (Fig. 2A), whereas serum anti-U1RNP Abs were 
detected frequently (71%).  
Correlation of anti-U1RNP index to CSF IL-6 level and Qalb. The anti-U1RNP 
index was compared to CSF IL-6 and Qalb determined from the same samples in 10 CSF 
anti-U1RNP Ab-positive patients (# 1–9, and 15). The anti-U1RNP index was independent 
of the CSF IL-6 (Fig. 2C) and anti-U1RNP ratio was not correlated to the IgG indices (Fig. 
2D). Qalb, which is reportedly a useful BBB permeability indicator, tended to inversely 
correlate with the anti-U1RNP index (Fig. 2C, y = -0.246x + 9.37). 
Anti-70K Abs were most dominant in CSF among the Abs against 
U1RNP-specific proteins. Anti-U1RNP Abs usually recognize either U1-70K, A, or C 
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proteins, which are the unique components of the U1RNP particle. We examined the 
anti-70K, A, and C indices as well as the anti-U1RNP index in eight CSF anti-U1RNP 
Ab-positive patients with central NPSLE (refer to Table 1), and the anti-U1RNP index was 
greater than 2.0 in all patients. In the same samples, there was an elevation of the anti-70K 
index (> 1.0) in seven of eight patients, whereas the anti-A and C indices were elevated in 
only a few patients. The average anti-70K index was significantly higher than that of the 
anti-C index and tended to be higher than that of the anti-A index (Fig. 3). 
U1-70K autoantigenic regions recognized by serum and CSF anti-U1RNP Abs. 
More detailed reactivity of the U1-70K protein was examined in sera and CSF from eight 
patients with CSF anti-U1RNP Abs. All prepared synthetic peptides were recognized by the 
eight anti-U1RNP Ab-positive sera, whereas there were 4–21 reacted residues for each serum 
sample (data not shown). Serum anti-U1RNP Abs in patients with central NPSLE bound the 
61–84 aa residue most frequently (88%) (Fig. 4). In contrast, the synthetic peptides that 
bound CSF anti-U1RNP Abs were limited to 20 residues, and 1–12 was the reacted residue 
number for each CSF sample (data not shown). The 141–164 aa residue alone was 
recognized by the majority of the CSF anti-U1RNP Abs (88%), whereas autoepitope pattern 
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recognized by serum- and CSF-anti-U1RNP Abs was not significantly different (Fig. 4).  
 
DISCUSSION 
We showed that CSF anti-U1RNP Abs determined by RNA-IPP and/or an elevation in the 
anti-U1RNP index are more specific markers for central NPSLE than the CSF IL-6 and IgG 
indices in serum anti-U1RNP Ab-positive SLE and MCTD patients. This is the first report 
showing the clinical significance of CSF anti-U1RNP Abs. While other autoAbs such as 
anti-ribosomal P, NR2, or dsDNA Abs in association with NPSLE have been described, 
there is no report regarding serum or CSF anti-U1RNP Abs in an international cohort or 
large study (26, 27). Recently, the sensitivity and specificity of CSF IL-6 (>4.3 pg/mL) for 
diagnosing central NPSLE have been reported as 87.5% and 92.3%, respectively (25). 
However, CSF IL-6 is not specific for disease-associated NPSLE because an IL-6 elevation 
can also be caused by infectious meningoencephalitis and cerebrovascular disease. The IgG 
index is also elevated in patients without CNS involvement (28), and no statistical 
differences in IL-6 and the IgG index were observed between central NPSLE and other CNS 
manifestations in the present study. Qalb elevation is strong evidence for BBB damage (22), 
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and more than half of our patients with central NPSLE had increased BBB permeability, 
similar to that reported in a previous study (29). However, the BBB damage is caused not 
only by central NPSLE but also by other factors. Qalb was elevated in patients with 
drug-induced aseptic meningitis (# 21) and miliary tuberculosis (# 22). The presence of 
anti-U1RNP Abs in CSF along with an anti-U1RNP index of more than 2.0 was frequently 
observed in patients with, but not without, central NPSLE (sensitivity = 64.3%, specificity = 
92.9%). Moreover, the sensitivity and specificity of CSF anti-U1RNP Abs for central 
NPSLE in serum anti-U1RNP Ab-positive patients were calculated as 81.8% and 90.0%, 
respectively, While global penetration of serum Abs into CSF occurs from a serious BBB 
injury, elevation of the anti-U1RNP index is not influenced, because the IgG ratio increases 
simultaneously in this condition. Thus, the increased anti-U1RNP Ab titer is a possible 
diagnostic marker for CNS manifestations attributable to SLE or MCTD independent of CSF 
IL-6 level, IgG index, or Qalb.  
In a previous study, a correlation was observed between serum anti-Sm Abs and 
central NPSLE (30), whereas the present study demonstrated no association between the 
presence of serum anti-U1RNP/Sm Abs and central NPSLE. To date, only our group (31) 
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and a German group (32) have published case reports of CSF anti-U1RNP Ab-positive 
patients. The important point of our study may be the use of RNA-IPP for detecting 
anti-U1RNP Abs. RNA-IPP is the most sensitive and specific method among the 
immunological methods used for detecting Abs, especially against RNA or RNA-binding 
proteins (33). The absence of anti-Sm Abs may not be due to a sensitivity problem with the 
RNA-IPP, because we could not detect the Abs in the same samples by ELISA. Because of 
the lower amount of cellular SSA-RNAs than U1RNAs, SSA-RNAs are more difficult to 
visualize than U1RNAs by RNA-IPP. It is possible that anti-U1RNP Abs were 
unequivocally detected in this system, and the present study may not indicate that an 
intrathecal ANA stimulation is specific to anti-U1RNP Abs.  
The striking deficit in CNS pathology, specifically the lack of vasculitis or massive 
cellular infiltrate in patients dying of central NPSLE, suggests that the pathogenesis differs 
from immune complex (IC) deposition, which is a characteristic of lupus nephritis. Rather, 
anti-U1RNP Abs may act as an inducer of proinflammatory cytokines. It is worth noting that 
serum and CSF of patients with NPSLE show abnormally high IFN-α-inducing activity (15). 
In addition to IFN-α and IC formed by CSF, autoAbs produce significantly increased levels 
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of IFN-γ-inducible protein 10 (IP-10/CXCL), IL-8, and monocyte chemotactic protein-1 
(34-36), and this phenomenon is most distinguished in the serum of anti-U1RNP Ab-positive 
patients (15). It is interesting that this hypothesis was demonstrated, because IFN-α is 
strongly induced by U1RNP-containing IC (37) and is the key cytokine for SLE 
pathogenesis. IC and IFN-α were not detected in most of our CSF samples (data not shown), 
possibly because CSF IFN-α was disrupted quickly and IC moved to FcγR-expressing cells.    
Thus far, it has been reported that a certain ANA subset is relevant to central NPSLE. 
First, serum anti-ribosomal P Abs are definitely a useful diagnostic marker for SLE (38); 
however, it is controversial whether anti-ribosomal P Abs in serum and/or CSF are a link to 
central NPSLE or not (11, 38), whereas the presence of ribosomal P protein on the 
endothelial cells has been demonstrated (39). It is likely that anti-ribosomal P Abs might not 
be able to pass effectively through the BBB due to binding to CNS endothelial cells (8). 
When paired serum and CSF samples were diluted to the same IgG concentrations and used 
for Western blotting, selective enrichment of IgG anti-ribosomal P occurred in the CSF of a 
few patients (39). Anti-ribosomal P Abs were not detected in CSF from our patients. Second, 
Kowal et al. have reported that a certain anti-dsDNA Ab subset in CSF, which cross-reacts 
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with the NR2 glutamate receptor, causes apoptotic neuronal death in the mouse hippocampus 
(3). Although the CSF level of anti-NR2 Abs was higher in patients with central NPSLE than 
that in other SLE groups, the highest CSF anti-NR2 Ab levels have been detected in patients 
with septic meningitis (26), suggesting that anti-NR2 Abs attack neurotransmitters directly 
through a breach in BBB integrity. While serum and CSF anti-NR2 Abs were not 
investigated in the present study, the anti-NR2 Ab-mediated neuronal diseases are different 
than aseptic meningitis and appear to be associated with anti-U1RNP Abs. Unfortunately, the 
present study did not clearly indicate which types of central NPSLE that anti-U1RNP Abs 
are most associated with. In accordance with a previous study (27), our data show no 
significant correlation between the presence of serum- or CSF-anti-SSA Abs and central 
NPSLE.  
The presence of ANA in CSF can be explained by three mechanisms: (1) in situ Ab 
production in the CNS, (2) a BBB breach, which would allow Abs to cross a normally 
restricted compartment, and (3) an increased Ab concentration resulting from a reduced CSF 
flow rate. However, our data strongly suggest intrathecal production of anti-U1 RNP Abs, 
because the anti-70K, A, and C indices were not equally elevated, and the anti-U1RNP and 
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70K indices in most patients increased by more than 2.0. Even if a BBB breach or reduced 
flow occurred, it is unlikely that either anti-70K, A, or C Abs penetrated or moved outside 
the CSF. The observation that a different U1-70K peptide recognition pattern by serum and 
CSF anti-70K Abs is evident also suggests intrathecal anti-U1RNP Ab production. 
Remarkably, the autoantigenic 141–164 aa residue for CSF anti-70K Abs in patients with 
central NPSLE was located within the RNA-binding domain (92–202 aa), including T (40) 
and B (41–44) cell major epitopes of human anti-70K Abs. Guldner et al. identified the 
56–195 aa domain as the major antigenic epitope recognized by all tested sera (41). Cram et 
al. reported the 100–156 aa residue as one of the major epitopes in the human 70K protein 
(42). James et al. showed that the basic aa-rich sequences are the early autoantigenic 
determinants of the 70K C-terminus (45). More detailed experiments using a large number of 
CSF samples are necessary to clarify the immunological characteristics of intrathecal 
anti-U1RNP Abs, whereas our results suggest the possibility that an ANA production in CSF 
is stimulated by an antigen-driven mechanism. 
In conclusion, CSF anti-U1RNP Abs, which may be produced in the CNS, are a 
clinically useful indicator for central NPSLE. However, there are some limitations to the 
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present study. First, the usefulness of the anti-U1RNP index is limited to patients with 
NPSLE that have serum anti-U1RNP Abs. Second, RNA-IPP method may be required to 
determine a low anti-U1RNP Ab titer, and third, our results were observed in a small number 
of Japanese patients. A more detailed association of CSF anti-U1RNP Abs with other 
humoral factors or activated neuronal cells in the CNS should be elucidated in a future study. 
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Figure 1. Antinuclear antibody (ANA) detection in sera and CSF by the RNA immunoprecipitation (RNA-IPP) assay. Anti-U1RNP and anti-SS-A/Ro 
(SSA) Abs precipitated U1RNA and SSA-RNA, respectively. CNS manifestations are listed in Table 1 and 2. (A) Serum and CSF samples from 
representative patients with central neuropsychiatric systemic lupus erythematosus (NPSLE). (B) Serum and CSF samples from representative patients 
without central NPSLE.  
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Figure 2. (A) ANA frequency difference in CSF from patients with and without central neuropsychiatric systemic lupus erythematosus (NPSLE). The 
frequency (%) of CSF ANA-positive in serum ANA-positive patients was shown. Anti-U1RNP and SS-A/Ro Abs were determined by RNA-IPP, and 
anti-dsDNA Abs were determined by ELISA. Anti-SSB/La and ribosomal P Abs were not detected in CSF. ANA, antinuclear antibodies; CSF, cerebrospinal 
fluid; IL-6, interleukin-6; Pts, patients; SSA, SS-A/Ro; N.S., not significant. (B) Comparison of the IgG and anti-U1RNP ratios. (C) Correlations between 
the anti-U1RNP index and IL-6, or Qalb. (D) Correlation between the anti-U1RNP ratio and the IgG index. The Pearson’s product moment correlation 
coefficients (r) were calculated in 10 patients with positive CSF anti-U1RNP Abs. IgG ratio = (CSF IgG concentration [mg/dL]/serum IgG concentration 
[mg/dL]), Anti-U1RNP ratio (with a compensation for the difference in serum/CSF dilutions) = (100/5) × (CSF anti-U1RNP Ab arbitrary units/serum 
anti-U1RNP Ab arbitrary units), Qalb (Albumin quotient, normal < 0.0076) = albumin ratio = (CSF albumin concentration [mg/dL]/serum albumin 
concentration [mg/dL]), IgG index = IgG ratio (CSF IgG concentration [mg/dL]/serum IgG concentration [mg/dL])/Qalb, Anti-U1RNP index = (anti-U1RNP 
ratio/IgG ratio) 
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Figure 3. Anti-U1RNP index in eight patients with central neuropsychiatric systemic lupus erythematosus (left) and the anti-70K, A, and C indices in the 
same patients (right) are shown. Serum and cerebrospinal fluid anti-70K, A, and C Ab titers were determined by ELISA using recombinant proteins. The 
patient number corresponds to the Pt number in Table 1. Because an insufficient quantity of sample was obtained from Pt.1, the Pt.1 index was excluded 
from this experiment.  
Anti-U1RNP, 70K, A, and C indices (with a compensation for the serum/CSF dilution difference) = (100/5) × ([CSF Ab arbitrary units/serum Ab arbitrary 
units]/[IgG ratio]) 
Pt, patient; N.S., not significant 
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Figure 4. Autoantigenic peptide residues recognized by serum and 
CSF anti-70K Abs from patients with neuropsychiatric systemic lupus 
erythematosus (NPSLE). The major autoantigenic domains for serum 
and CSF anti-U1-70K Abs were examined using ELISA with 22 
overlapping peptides identical with the partial sequence of U1-70K 
(17–24 amino acids [aa]). Sera and CSF from eight patients with 
central NPSLE were diluted to 100 µg/mL and positivity was 
determined as more than the mean + 2SD of the negative control 
samples obtained from patients without serum and CSF anti-U1RNP 
Abs. The data show the positive frequency of anti-peptide Abs in eight 
serum and CSF samples from CSF anti-U1RNP Ab-positive patients 
with central NPSLE.  
CSF, cerebrospinal fluid   
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Figure 1. Antinuclear antibody (ANA) detection in sera and CSF by the RNA 
immunoprecipitation (RNA-IPP) assay. Anti-U1RNP and anti-SS-A/Ro (SSA) Abs 
precipitated U1RNA and SSA-RNA, respectively. CNS manifestations are listed in Table 1 
and 2. (A) Serum and CSF samples from representative patients with central 
neuropsychiatric systemic lupus erythematosus (NPSLE). (B) Serum and CSF samples from 
representative patients without central NPSLE.  
Pt, patient; T, Total RNAs; S, serum; C, cerebrospinal fluid 
 
Figure 2. (A) ANA frequency difference in CSF from patients with and without central 
neuropsychiatric systemic lupus erythematosus (NPSLE). The frequency (%) of CSF 
ANA-positive in serum ANA-positive patients was shown. Anti-U1RNP and SS-A/Ro Abs 
were determined by RNA-IPP, and anti-dsDNA Abs were determined by ELISA. 
Anti-SSB/La and ribosomal P Abs were not detected in CSF. ANA, antinuclear antibodies; 
CSF, cerebrospinal fluid; IL-6, interleukin-6; Pts, patients; SSA, SS-A/Ro; N.S., not 
significant. (B) Comparison of the IgG and anti-U1RNP ratios. (C) Correlations between the 
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anti-U1RNP index and IL-6, or Qalb. (D) Correlation between the anti-U1RNP ratio and the 
IgG index. The Pearson’s product moment correlation coefficients (r) were calculated in 10 
patients with positive CSF anti-U1RNP Abs. 
IgG ratio = (CSF IgG concentration [mg/dL]/serum IgG concentration [mg/dL]) 
Anti-U1RNP ratio (with a compensation for the difference in serum/CSF dilutions) = (100/5) 
× (CSF anti-U1RNP Ab arbitrary units/serum anti-U1RNP Ab arbitrary units) 
Qalb (Albumin quotient, normal < 0.0076) = albumin ratio = (CSF albumin concentration 
[mg/dL]/serum albumin concentration [mg/dL]) 
IgG index = IgG ratio (CSF IgG concentration [mg/dL]/serum IgG concentration 
[mg/dL])/Qalb 
Anti-U1RNP index = (anti-U1RNP ratio/IgG ratio)  
 
Figure 3. Anti-U1RNP index in eight patients with central neuropsychiatric systemic lupus 
erythematosus (left) and the anti-70K, A, and C indices in the same patients (right) are 
shown. Serum and cerebrospinal fluid anti-70K, A, and C Ab titers were determined by 
ELISA using recombinant proteins. The patient number corresponds to the Pt number in 
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Table 1. Because an insufficient quantity of sample was obtained from Pt.1, the Pt.1 index 
was excluded from this experiment.  
Anti-U1RNP, 70K, A, and C indices (with a compensation for the serum/CSF dilution 
difference) = (100/5) × ([CSF Ab arbitrary units/serum Ab arbitrary units]/[IgG ratio]) 
Pt, patient; N.S., not significant 
 
Figure 4. Autoantigenic peptide residues recognized by serum and CSF anti-70K Abs from 
patients with neuropsychiatric systemic lupus erythematosus (NPSLE). The major 
autoantigenic domains for serum and CSF anti-U1-70K Abs were examined using ELISA 
with 22 overlapping peptides identical with the partial sequence of U1-70K (17–24 amino 
acids [aa]). Sera and CSF from eight patients with central NPSLE were diluted to 100 µg/mL 
and positivity was determined as more than the mean + 2SD of the negative control samples 
obtained from patients without serum and CSF anti-U1RNP Abs. The data show the positive 
frequency of anti-peptide Abs in eight serum and CSF samples from CSF anti-U1RNP 
Ab-positive patients with central NPSLE.  
CSF, cerebrospinal fluid   
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Table 1. Patient profiles with central NPSLE
CNS Cell number Total protein IL-6 IgG Q alb ANA ANA Anti-U1RNP Treatment
Pt Age Diagnosis  manifestations in CSF in CSF in CSF index (×103)  in serum in CSF index for CNS manifestations
(/µl) (mg/dl) (pg/ml)
1 32 SLE H 0 14 1.0 0.89 1.9 U1, DNA, Sm U1 13.6 high-dose CS
2 30 SLE AsM, CgD 5 31 3.2 0.76 3.7 U1, DNA, SSA, Sm, U1, SSA 12.4 mPSL pulse, high-dose CS, 
tRNA, riboP CyA, IVCY
3 29 MCTD AsM 11 81 3240 0.72 15.7 U1, SSA, riboP U1, SSA 9.4 high-dose CS
4 43 MCTD Psy 3 49 1.5 0.77 7.2 U1, U2 U1 8.8 mPSL pulse, high-dose CS, IVCY 
5 20 SLE CgD, Psy 0 48 2.3 0.62 8.1 U1, SSA, Sm, riboP U1 7.6 mPSL pulse, IVCY, DFPP, rituximab
6 40 MCTD AsM, CgD 40 155 837 0.59 30.3 U1, DNA U1 3.0 high-dose CS, IVCY
7 22 SLE ACS, AsM, CVD 32 132 7.8 0.77 20.4 U1, Sm, riboP U1 2.2 high-dose CS, IVCY 
8 32 SLE AsM 14 128 1190 0.80 18.6 U1, DNA, SSA, SSB U1, SSA 2.1 mPSL pulse, high-dose CS
9 39 SLE MovD, H 4 20 1.9 0.61 2.8 U1, SSA U1 2.1 mPSL pulse, high-dose CS
10 26 SLE H, Psy 3 29 644 0.83 8.6 U1, SSA negative ND high-dose CS
11 58 SLE Se, CgD 0 30 2.6 0.55 5.7 U1, SSA negative ND low-dose CS
12 41 SLE DemS 3 119 ND 0.68 18.6 DNA, SSA DNA* ND high-dose CS, IVCY 
13 56 SLE H, Se 1 35 2.0 0.68 4.5 DNA negative ND mPSL pulse
14 29 SLE ACS, Psy 1 52 ND 0.65 9.5 negative negative ND high-dose CS, rituximab
mean±SD 8±13 66±48 494±958 0.71±0.10 11.1±8.3 6.8±4.6
           
Pt= patient, CNS= central nervous system, CSF= cerebrospinal fluid, Q alb= albumin quotient, ANA= antinuclear antibodies,
SLE= systemic lupus erythematosu, MCTD= mixed connective tissue disease, 
H= intractable headache associated with SLE, AsM= aseptic meningitis, CgD= cognitive dysfunction, Psy= psychosis, ACS= acute confusional state, CVD= cerebrovascular disease, 
MovD= movement disorder, DemS= demyelinating syndrome, Se= seizures and seizure disorders,
U1= anti-U1RNP Abs, SSA= anti-SS-A/Ro Abs, Sm= anti-Sm Abs, tRNA= anti-transfer RNA Abs, riboP= anti-ribosomal P Abs, U2= anti-U2RNP Abs, DNA= anti-dsDNA Abs, 
mPSL= methylprednisolone, CS= corticosteroid, CyA= cyclosporine A,  IVCY= intravenous cyclophosphamide, DFPP= double-filtration plasmapheresis, 
ND= not determined
*Anti-dsDNA Abs in CSF were determined by ELISA using negative controls (refer to PATIENTS AND METHODS ).
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Table 2. Patient profiles without central NPSLE
Age at Diagnosis CNS manifestations Cell number Total protein IL-6 IgG index Q alb×103 ANA in serum ANA in CSF Effective treatment
Pt CNS manifestation in CSF in CSF in CSF for CNS manifestations
onset (/µl) (mg/dl) (pg/ml)
15 29 SLE AxD 1 31 1.9 1.25 4.3 U1RNP*, DNA, SSA U1RNP*, SSA flunitrazepam, cloxazolam
16 19 SLE H 1 55 20.1 1.38 7.4 U1RNP, DNA, SSA negative NSAIDs
17 24 SLE Se 0 20 1.0 0.59 3.1 U1RNP, DNA, SSA, Sm negative sodium valproate
18 28 SLE CgD 1 22 1.2 0.43 3.6 U1RNP, Sm negative diazepam
19 49 SLE CVD 1 31 ND 0.43 5.6 U1RNP, DNA, Sm negative low dose of aspirin
20 22 SLE CVD 1 36 ND 0.62 5.5 U1RNP, DNA negative low dose of aspirin
21 42 MCTD Drug-induced AsM 10 54 59.1 0.57 12.4 U1RNP, DNA negative withdrawal of NSAIDs
22 38 SLE Miliary tuberculosis 233 214 48300 0.83 31.9 U1RNP, DNA negative antitubercular drugs
23 25 SLE Steroid-induced psychosis 11 31 8.3 0.98 5.6 U1RNP, DNA, SSA negative decrease of CS dose
24 32 SLE Steroid-induced psychosis 1 26 1.4 0.74 4.5 U1RNP, SSA negative decrease of CS dose
25 37 SLE CVD 3 48 ND 0.76 7.6 DNA, SSA DNA** low dose of aspirin
26 44 SLE, APS CVD 4 53 ND 0.57 6.2 DNA, SSA negative warfarin
27 31 SLE H (migraine) 0 21 0.5 ND ND DNA negative zolmitriptan
28 41 SLE Steroid-induced psychosis 0 19 0.8 0.80 2.9 SSA negative decrease of CS dose
mean±SD 19±62 47±50 4839±15270 0.77±0.29 7.7±7.7 
      
Pt= patient, CNS= central nervous system, CSF= cerebrospinal fluid, Q alb= albumin quotient, ANA= antinuclear antibodies, SLE= systemic lupus erythematosus,
MCTD=  mixed connective tissue disease, APS= anti-phospholipid Ab syndrome,
AxD= anxiety disorder, H= intractable headache unrelated to SLE, Se= seizures and seizure disorders, CgD= cognitive dysfunction, CVD= cerebrovascular disease,
AsM= aseptic meningitis,
U1= anti-U1RNP Abs, SSA= anti-SS-A/Ro Abs, Sm= anti-Sm Abs, tRNA= anti-transfer RNA Abs, riboP= anti-ribosomal P Abs, U2= anti-U2RNP Abs, DNA= anti-dsDNA Abs, 
NSAIDs= non-steroidal anti-inflammatory drugs, CS= corticosteroid.
ND= not determined
*anti-U1RNP index = 4.7 
**Anti-dsDNA Abs in CSF were determined by ELISA using negative controls (refer to PATIENTS AND METHODS ).
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Objective. To determine the significance of anti-U1 ribonucleoprotein (RNP) 
antibodies (Abs) in cerebrospinal fluid (CSF) from systemic lupus erythematosus (SLE) and 
mixed connective tissue disease (MCTD) patients with central neuropsychiatric (NP) SLE.  
Methods. Antinuclear Abs including anti-U1RNP Abs were determined in sera and 
CSF of 24 patients with SLE and four patients with MCTD and central NPSLE using an 
RNA immunoprecipitation assay and ELISA. The frequency of CSF anti-U1RNP Abs in 
patients with central NPSLE was examined, and the anti-U1RNP index (= [CSF anti-U1RNP 
Abs /serum anti-U1RNP Abs] / [CSF IgG /serum IgG]) was compared with CSF interleukin 
(IL)-6 levels and the albumin quotient (Qalb, an indicator of blood brain barrier damage). 
CSF and serum Abs against U1-70K, A, and C including autoantigenic regions were 
examined, and the anti-70K, A, and C indices as well as the anti-U1RNP index were 
calculated.   
Results. CSF anti-U1RNP Abs with an increased anti-U1RNP index showed 64% 
sensitivity and 93% specificity for central NPSLE. The anti-U1RNP index did not correlate 
with CSF IL-6 levels or Qalb. The anti-70K index was higher than the anti-A and C indices 
in CSF of anti-U1RNP Ab-positive patients with central NPSLE. The major autoantigenic 
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region for CSF anti-70K Abs appeared to be localized in the U1-70K 141–164 amino acid 
residues within the RNA-binding domain.  
Conclusions. CSF anti-U1RNP Abs and the anti-U1RNP index are useful indicators 
for central NPSLE in anti-U1RNP Ab-positive patients. The predominance of anti-70K Abs 
in CSF suggests intrathecal anti-U1RNP Ab production.  
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Systemic lupus erythematosus (SLE) is a chronic, remitting and relapsing, 
multisystem autoimmune disease that predominantly affects women. Among various organ 
damages, neuropsychiatric SLE involving the central nervous system (CNS; central NPSLE) 
is a life-threatening severe manifestation. The overall prevalence of NPSLE varies between 
14 and 75% in a representative selection of studies using the American College of 
Rheumatology (ACR) nomenclature (1). In fact, NPSLE may affect mortality in SLE and is 
associated with a significant negative impact on a patients’ quality of life. However, 41% of 
all CNS manifestations in SLE patients may be attributed to factors other than lupus (2).  
Although the pathophysiology of most NPSLE cases is not well determined, a 
particular subset of autoantibodies (Abs) is associated with neuronal injury. A subset of 
anti-DNA Abs cross-reacts with a sequence within the N-methyl-D-aspartate receptor subunit 
NR2 (anti-NR2 Abs), causing excitatory synaptic transmission in the CNS (3). Anti-NR2 
Abs preferentially target the hippocampus, suggesting that anti-NR2 Abs may disrupt normal 
cognitive processes (4). However, serum anti-NR2 Abs may be associated with depressive 
mood (5), but not cognitive dysfunction (5, 6). Arinuma et al. (7) reported that anti-NR2 Abs 
in cerebrospinal fluid (CSF), but not in serum, were involved in diffuse central NPSLE. 
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Anti-ribosomal P Abs have been reported as neurotoxic autoAbs (8–10). Abnormal behavior 
can be induced in normal mice by administering anti-ribosomal P Abs (10), although serum 
anti-ribosomal P Abs are not specific to human central NPSLE (11). In association with 
thrombosis, anti-β2-glycoprotein I and prothrombin Abs are recognized as pathogenic Abs in 
focal central NPSLE such as cerebrovascular disease (12).  
In addition to autoAbs, several proinflammatory cytokines and chemokines have 
been detected in serum and CSF of patients with SLE. The most important cytokine in SLE 
and NPSLE may be interferon (IFN)-α (13–15). A recent report showed the presence of 
IFN-α, IFN-γ-inducible protein 10 (IP-10), interleukin (IL)-8, and monocyte chemotactic 
protein (MCP)-1 in the CSF from patients with NPSLE (15). IFN-α generation in SLE is 
caused, at least partially, by autoAbs that bind to ribonucleoprotein (RNP) particles released 
from dead and dying cells. Santer et al. clearly suggested that IFN-inducing activity in CSF 
correlates with serum anti-U1RNP Abs, but not with other known antinuclear antibodies 
(ANA) (15). Therefore, anti-U1RNP Abs and their immune complex in CSF may have 
pathogenic roles in central NPSLE. Okada et al. reported 14 patients with aseptic meningitis 
(eight with SLE, six with mixed connective tissue disease [MCTD] or undifferentiated 
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connective tissue disease, and one with Sjögren’s syndrome) among 1560 patients with 
connective tissue disease. Serum anti-U1RNP Abs were positive in 13 of the 14 patients with 
aseptic meningitis, suggesting that anti-U1RNP Abs may be linked to central NP 
manifestations (16). In the present study, we evaluated the clinical significance and 
immunological characteristics of anti-U1RNP Abs in CSF derived from SLE and MCTD 
patients with central NP manifestations.  
 
PATIENTS AND METHODS 
Patients. Patients with SLE or MCTD who revealed CNS manifestations and had 
been admitted to the Department of Rheumatology and Clinical Immunology, Kyoto 
University Hospital, from March 2002 to October 2007 were enrolled. SLE was diagnosed 
according to the ACR criteria (17, 18) and MCTD was diagnosed according to the criteria 
proposed by the Ministry of Health and Welfare in Japan (19). CNS manifestations were 
classified according to the case definitions for NP syndromes in SLE (20). Evaluation of NP 
syndromes included neuropsychiatric testing and magnetic resonance imaging (MRI) of the 
brain. Patients were diagnosed with central NPSLE retrospectively, according to 
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Kwiecinski’s criteria (21) with some modifications. Briefly, central NPSLE was defined as 
the presence of at least two of the following six items: 1) recent-onset of psychosis, 2) 
transverse myelitis, 3) aseptic meningitis, 4) seizures, 5) pathologic changes visualized on 
brain MRI, and 6) severely abnormal cognitive dysfunction documented by neuropsychiatric 
testing. Oligoclonal IgG bands in the CSF were not included, and CNS manifestations 
caused by other factors (e.g., concurrent non-SLE NP disease such as infection and 
secondary NPSLE such as uremia, hypertension, and complications of SLE therapy) were 
not defined as central NPSLE. In the present study, small punctate focal lesions in white 
matter, cortical atrophy, periventricular white matter hyperintensity, diffuse white matter 
changes, discrete gray matter lesions, diffuse gray matter hyperintensities, cerebral edema, 
and new infarct were considered as pathologic changes on brain MRI. The present study was 
conducted in compliance with the Declaration of Helsinki and approved by the Kyoto 
University Ethics Committee Review Board (approval #E97).  
Samples.  After an acute phase of massive cerebrovascular disease (CVD) was 
ruled out by brain MRI screening, CSF was taken from patients within 3 days from the onset 
of CNS manifestations. We have a written informed consent from all of the studied patients. 
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Serum samples were collected from all patients on the same day, and both samples were 
stored at -80°C. Routine CSF and serum analyses, including total protein, albumin, and IgG 
level, were conducted. CSF interleukin (IL)-6 (R&D Systems, Minneapolis, MN, USA) and 
interferon (IFN)-α (Bender MedSystems, Vienna, Austria) levels were determined by ELISA, 
according to the manufacturer’s protocol. The sensitivity of the IFN-α assay was more than 
5 pg/mL. 
Qalb and IgG index. To determine blood brain barrier (BBB) damage, the albumin 
quotient (Qalb, normal < 0.0076) was calculated as the ratio of CSF albumin (mg/dL) to 
serum albumin (mg/dL) (22). The IgG index was calculated as the IgG ratio (CSF IgG 
concentration [mg/dL] /serum IgG concentration [mg/dL])/Qalb.  
Detection of antinuclear antibodies (ANA) in sera and CSF by RNA 
immunoprecipitation. RNA immunoprecipitation (RNA-IPP) using HeLa cell extracts was 
performed to determine anti-RNA-associated antigen Abs, such as anti-U1RNP, Sm, 
SS-A/Ro (SSA), SS-B/La (SSB), and ribosomal P Abs in sera and CSF (23). A 10 µl sample 
of sera or CSF was mixed with 2 mg of protein A SepharoseTM CL-4B (GE Healthcare, 
Upsala, Sweden) in 500 µl of IPP buffer (10 mM Tris-HCl at pH 8.0, 500 mM NaCl, 0.1% 
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Nonidet P-40 [NP-40]) and incubated on a rotator for 2 h at 4°C. The IgG-coated Sepharose 
was washed four times in 500 µl of IPP buffer using 10-s spins in a microfuge and 
resuspended in 400 µl of NET-2 buffer (50 mM Tris-HCl at pH 7.5, 150 mM NaCl, 0.05% 
NP-40). For RNA analysis, this suspension was incubated with 300 µl of HeLa cell extracts, 
derived from 6 × 106 cells, on a rotator for 2 h at 4°C. The antigen-bound Sepharose was 
then collected by a 10-s centrifugation in a microfuge, washed four times with 500 µl of 
NET-2 buffer, and resuspended in 270 ml of NET-2 buffer. To extract bound RNAs, 30 µl of 
3.0 M sodium acetate, 15 µl of 20% sodium dodecyl sulfate, and 300 µl of 
phenol/chloroform/isoamyl alcohol (50:50:1; containing 0.2 g of 8-hydroxyquinoline and 40 
ml of 0.1 M Tris-HCl at pH 7.5) were added to the Sepharose beads. After agitation in a 
vortex mixer and spinning for 1 min, RNAs were recovered in the aqueous phase after 
ethanol precipitation and dissolved in 20 µl of electrophoresis sample buffer composed of 10 
M urea, 0.025% bromphenol blue, and 0.02 % xylene cyanol FF (Bio-Rad, Hercules, CA, 
USA) in Tris-borate-EDTA buffer (90 mM Tris HCl at pH 8.6, 90 mM boric acid, and 1 mM 
EDTA). The RNA samples were denatured at 65°C for 5 min and then resolved by 7 M 
urea-10% polyacrylamide gel electrophoresis with silver staining (Bio-Rad). Anti-U1RNP, 
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Sm, SSA, and SSB Abs were determined as positive when U1RNA, U1-U6RNA, SSA-RNA 
(Y1-Y5RNA), and SSB-RNA (5S-ribosomal RNA, 7S-RNA, and Y1-Y5RNA) were 
precipitated, respectively.  
Detection of ANA in sera and CSF by ELISA. Serum anti-U1RNP, dsDNA, SSA, 
and ribosomal P Abs were also determined by ELISA using recombinant U1RNP 
(Mesacup®-2 test RNP, Medical and Biological Laboratories [MBL] Co., Nagoya, Japan), 
purified dsDNA (Mesacup DNA-II t st ds®, MBL Co.), recombinant SS-A (Mesacup®-2 test 
SS-A, MBL Co.), and recombinant ribosomal P proteins (Ribosomal P ELISA kit, MBL Co.), 
according to the manufacturer’s protocol. Anti-ribosomal P and dsDNA Abs in CSF were 
determined to be positive when the experimental titer was more than that of the mean + 2SD 
of 10 negative controls. CSF samples derived from patients with other autoimmuine diseases 
(4 with polyarteritis nodosa, 4 with multiple sclerosis, and 2 with rheumatoid arthritis) were 
used as negative CSF controls for the anti-ribosomal P and dsDNA Abs. These patients had 
CNS manifestation and/or CSF abnormality, but not NPSLE, and negative results for their 
serum ANA were confirmed. Sera were diluted 1:100, and CSF samples were diluted 1:5 
using phosphate buffer saline (PBS). To determine the levels of anti-70K, A, and C Abs, 
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recombinant U1-70K, A, and C (MBL Co.) along with coating buffer (pH 9.4) (1 µg/mL) 
were bound to ELISA plates, and the wells were blocked using 5% bovine serum albumin 
(BSA) in PBS. Patient sera and CSF containing anti-U1RNP Abs were added and incubated 
at room temperature for 2 h, followed by detection of bound IgG with alkaline 
phosphatase-conjugated anti-human IgG (Southern Biotechnology Associates Inc., 
Birmingham, AL, USA) at OD405 nm in a microtiter ELISA reader. All assays were performed 
in triplicate. We confirmed that the OD405nm values of the CSF-experimental wells were 
included within the linear range of the positive control. If a 1:5 dilution was not appropriate, 
the dilution was changed in such samples and the obtained titer was adjusted. 
Anti-U1RNP ratio and anti-U1RNP index. Arbitrary units of the anti-U1RNP Abs 
in each sample were determined using serum and CSF anti-U1RNP Ab-positive (defined as 
100 units) and negative standard samples. More precisely, the arbitrary units for serum or 
CSF anti-U1RNP Abs were calculated as: ([OD405 nm of experimental well − OD405 nm of 
anti-U1RNP Ab-negative standard well] × 100/[OD405 nm of anti-U1RNP Ab-positive 
standard well − OD405 nm of anti-U1RNP Ab-negative standard well]). After obtaining the 
arbitrary units of the anti-U1RNP Ab, the anti-U1RNP ratio and anti-U1RNP index were 
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calculated as: (CSF arbitrary anti-U1RNP Ab units × 5/serum arbitrary anti-U1RNP Ab units 
× 100) and anti-U1RNP ratio/IgG ratio, respectively. The difference in the dilutions between 
serum (×100) and CSF (×5) was adjusted, and the anti-70K, A, and C indices were obtained 
by the same calculation method.  
Determination of autoantigenic regions recognized by serum and CSF anti-70K 
Abs. To compare the autoantigenic regions in the U1-70K proteins recognized by the CSF 
and serum anti-U1RNP Abs, we prepared 22 overlapping synthetic peptides (17–24 amino 
acids [aa]) identical with the U1-70K partial sequences (24) (Fig. 4). Synthetic peptides (100 
µg/ml) with coating buffer (pH 9.4) were bound to ELISA plates and the wells were blocked 
with 5% BSA in PBS. Sera and CSF from eight patients with central NPSLE were diluted to 
100 µg/mL with PBS and then incubated for 2 h at room temperature, followed by detection 
of bound IgG with alkaline phosphatase-conjugated anti-human IgG (Southern 
Biotechnology Associates Inc.) at OD405 nm in a microtiter ELISA reader. All assays were 
performed in triplicate. Positivity was determined as more than the mean + 2SD of the 
negative control samples obtained from patients without serum and CSF anti-U1RNP Abs. 
Statistical analysis. Differences in the frequencies of ANA in CSF and serum were 
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evaluated by the chi-square (χ2) test and Fisher’s exact test as appropriate. The Student’s 
t-test was used to compare the difference between two group means. Pearson’s product 
moment correlation coefficients (r) were calculated to evaluate the correlation between the 




Patient characteristics. NP syndromes were detected in 24 patients with SLE and 
four patients with MCTD. All patients were female, and their age at onset of CNS 
manifestations was 34.1 years (range, 19–58 years). According to the ACR nomenclature 
(20), the symptoms of central NPSLE exhibited by our patients were as follows: headache, 
cerebrovascular disease, cognitive dysfunction, seizures and seizure disorder, aseptic 
meningitis, psychosis, acute confusional state, demyelinating syndrome, anxiety disorder, 
and movement disorder.  
CSF findings and ANA profiles in patients with central NPSLE. Fourteen patients 
were diagnosed with central NPSLE (Table 1). All patients except for patient 11 needed a 
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high-dose corticosteroid treatment along with methylprednisolone pulse therapy and/or 
immunosuppressive agents for their central NPSLE. Aseptic meningitis most frequently 
occurred (five patients). Of the 14 patients, the cell number in CSF increased in six patients 
(46%, normal < 4 cells/µl), and total protein concentration increased in eight patients (57%, 
normal < 40 mg/dL). CSF IL-6 was elevated in five of 12 patients (42%, normal < 4.3 pg/mL 
[25]), and the IgG index increased in nine of 14 (64%, normal < 0.67). Qalb, an index of 
blood brain barrier (BBB) permeability, increased in eight of 14 patients (57%, normal < 
0.0076 [22]). By RNA-IPP, anti-U1RNP, SSA, SSB, and Sm Abs were detected in sera from 
11 (79%), eight (57%), one (7%), and four (29%) patients, respectively. Anti-ribosomal P 
and dsDNA Abs were determined as positive by ELISA in sera from four (29%) and six 
(43%) patients, respectively. In contrast, anti-U1RNP Abs in CSF were most frequently 
detected by RNA-IPP (82%) in CSF from anti-U1RNP Ab-positive patients with central 
NPSLE (Fig. 1 and 2A). The anti-U1RNP ratios increased more than the IgG ratios in 
patients with CSF-anti-U1RNP Abs (Fig. 2B). CSF anti-SSA and dsDNA Abs were detected 
in only three and one patient, respectively. Anti-ribosomal P and Sm Abs were absent in CSF.  
CSF findings and ANA profiles in patients without central NPSLE. CNS 
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manifestations were diagnosed in 14 patients as concurrent non-SLE central NP diseases or 
secondary central NP syndromes (Table 2). Increased cell number and protein concentrations 
were observed in three (21%) and five (36%) patients, respectively. IL-6, the IgG index, and 
Qalb were elevated in four (40%), seven (54%), and two (15%) out of 14 patients, 
respectively. These values were not significantly different between patients with and without 
central NPSLE. In contrast to central NPSLE, CSF anti-U1RNP Abs were detected in only 
one patient (#15) without central NPSLE (Fig. 2A), whereas serum anti-U1RNP Abs were 
detected frequently (71%).  
Correlation of anti-U1RNP index to CSF IL-6 level and Qalb. The anti-U1RNP 
index was compared to CSF IL-6 and Qalb determined from the same samples in 10 CSF 
anti-U1RNP Ab-positive patients (# 1–9, and 15). The anti-U1RNP index was independent 
of the CSF IL-6 (Fig. 2C) and anti-U1RNP ratio was not correlated to the IgG indices (Fig. 
2D). Qalb, which is reportedly a useful BBB permeability indicator, tended to inversely 
correlate with the anti-U1RNP index (Fig. 2C, y = -0.246x + 9.37). 
Anti-70K Abs were most dominant in CSF among the Abs against 
U1RNP-specific proteins. Anti-U1RNP Abs usually recognize either U1-70K, A, or C 
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proteins, which are the unique components of the U1RNP particle. We examined the 
anti-70K, A, and C indices as well as the anti-U1RNP index in eight CSF anti-U1RNP 
Ab-positive patients with central NPSLE (refer to Table 1), and the anti-U1RNP index was 
greater than 2.0 in all patients. In the same samples, there was an elevation of the anti-70K 
index (> 1.0) in seven of eight patients, whereas the anti-A and C indices were elevated in 
only a few patients. The average anti-70K index was significantly higher than that of the 
anti-C index and tended to be higher than that of the anti-A index (Fig. 3). 
U1-70K autoantigenic regions recognized by serum and CSF anti-U1RNP Abs. 
More detailed reactivity of the U1-70K protein was examined in sera and CSF from eight 
patients with CSF anti-U1RNP Abs. All prepared synthetic peptides were recognized by the 
eight anti-U1RNP Ab-positive sera, whereas there were 4–21 reacted residues for each serum 
sample (data not shown). Serum anti-U1RNP Abs in patients with central NPSLE bound the 
61–84 aa residue most frequently (88%) (Fig. 4). In contrast, the synthetic peptides that 
bound CSF anti-U1RNP Abs were limited to 20 residues, and 1–12 was the reacted residue 
number for each CSF sample (data not shown). The 141–164 aa residue alone was 
recognized by the majority of the CSF anti-U1RNP Abs (88%), whereas autoepitope pattern 
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recognized by serum- and CSF-anti-U1RNP Abs was not significantly different (Fig. 4).  
 
DISCUSSION 
We showed that CSF anti-U1RNP Abs determined by RNA-IPP and/or an elevation in the 
anti-U1RNP index are more specific markers for central NPSLE than the CSF IL-6 and IgG 
indices in serum anti-U1RNP Ab-positive SLE and MCTD patients. This is the first report 
showing the clinical significance of CSF anti-U1RNP Abs. While other autoAbs such as 
anti-ribosomal P, NR2, or dsDNA Abs in association with NPSLE have been described, 
there is no report regarding serum or CSF anti-U1RNP Abs in an international cohort or 
large study (26, 27). Recently, the sensitivity and specificity of CSF IL-6 (>4.3 pg/mL) for 
diagnosing central NPSLE have been reported as 87.5% and 92.3%, respectively (25). 
However, CSF IL-6 is not specific for disease-associated NPSLE because an IL-6 elevation 
can also be caused by infectious meningoencephalitis and cerebrovascular disease. The IgG 
index is also elevated in patients without CNS involvement (28), and no statistical 
differences in IL-6 and the IgG index were observed between central NPSLE and other CNS 
manifestations in the present study. Qalb elevation is strong evidence for BBB damage (22), 
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and more than half of our patients with central NPSLE had increased BBB permeability, 
similar to that reported in a previous study (29). However, the BBB damage is caused not 
only by central NPSLE but also by other factors. Qalb was elevated in patients with 
drug-induced aseptic meningitis (# 21) and miliary tuberculosis (# 22). The presence of 
anti-U1RNP Abs in CSF along with an anti-U1RNP index of more than 2.0 was frequently 
observed in patients with, but not without, central NPSLE (sensitivity = 64.3%, specificity = 
92.9%). Moreover, the sensitivity and specificity of CSF anti-U1RNP Abs for central 
NPSLE in serum anti-U1RNP Ab-positive patients were calculated as 81.8% and 90.0%, 
respectively, While global penetration of serum Abs into CSF occurs from a serious BBB 
injury, elevation of the anti-U1RNP index is not influenced, because the IgG ratio increases 
simultaneously in this condition. Thus, the increased anti-U1RNP Ab titer is a possible 
diagnostic marker for CNS manifestations attributable to SLE or MCTD independent of CSF 
IL-6 level, IgG index, or Qalb.  
In a previous study, a correlation was observed between serum anti-Sm Abs and 
central NPSLE (30), whereas the present study demonstrated no association between the 
presence of serum anti-U1RNP/Sm Abs and central NPSLE. To date, only our group (31) 
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and a German group (32) have published case reports of CSF anti-U1RNP Ab-positive 
patients. The important point of our study may be the use of RNA-IPP for detecting 
anti-U1RNP Abs. RNA-IPP is the most sensitive and specific method among the 
immunological methods used for detecting Abs, especially against RNA or RNA-binding 
proteins (33). The absence of anti-Sm Abs may not be due to a sensitivity problem with the 
RNA-IPP, because we could not detect the Abs in the same samples by ELISA. Because of 
the lower amount of cellular SSA-RNAs than U1RNAs, SSA-RNAs are more difficult to 
visualize than U1RNAs by RNA-IPP. It is possible that anti-U1RNP Abs were 
unequivocally detected in this system, and the present study may not indicate that an 
intrathecal ANA stimulation is specific to anti-U1RNP Abs.  
The striking deficit in CNS pathology, specifically the lack of vasculitis or massive 
cellular infiltrate in patients dying of central NPSLE, suggests that the pathogenesis differs 
from immune complex (IC) deposition, which is a characteristic of lupus nephritis. Rather, 
anti-U1RNP Abs may act as an inducer of proinflammatory cytokines. It is worth noting that 
serum and CSF of patients with NPSLE show abnormally high IFN-α-inducing activity (15). 
In addition to IFN-α and IC formed by CSF, autoAbs produce significantly increased levels 
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of IFN-γ-inducible protein 10 (IP-10/CXCL), IL-8, and monocyte chemotactic protein-1 
(34-36), and this phenomenon is most distinguished in the serum of anti-U1RNP Ab-positive 
patients (15). It is interesting that this hypothesis was demonstrated, because IFN-α is 
strongly induced by U1RNP-containing IC (37) and is the key cytokine for SLE 
pathogenesis. IC and IFN-α were not detected in most of our CSF samples (data not shown), 
possibly because CSF IFN-α was disrupted quickly and IC moved to FcγR-expressing cells.    
Thus far, it has been reported that a certain ANA subset is relevant to central NPSLE. 
First, serum anti-ribosomal P Abs are definitely a useful diagnostic marker for SLE (38); 
however, it is controversial whether anti-ribosomal P Abs in serum and/or CSF are a link to 
central NPSLE or not (11, 38), whereas the presence of ribosomal P protein on the 
endothelial cells has been demonstrated (39). It is likely that anti-ribosomal P Abs might not 
be able to pass effectively through the BBB due to binding to CNS endothelial cells (8). 
When paired serum and CSF samples were diluted to the same IgG concentrations and used 
for Western blotting, selective enrichment of IgG anti-ribosomal P occurred in the CSF of a 
few patients (39). Anti-ribosomal P Abs were not detected in CSF from our patients. Second, 
Kowal et al. have reported that a certain anti-dsDNA Ab subset in CSF, which cross-reacts 
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with the NR2 glutamate receptor, causes apoptotic neuronal death in the mouse hippocampus 
(3). Although the CSF level of anti-NR2 Abs was higher in patients with central NPSLE than 
that in other SLE groups, the highest CSF anti-NR2 Ab levels have been detected in patients 
with septic meningitis (26), suggesting that anti-NR2 Abs attack neurotransmitters directly 
through a breach in BBB integrity. While serum and CSF anti-NR2 Abs were not 
investigated in the present study, the anti-NR2 Ab-mediated neuronal diseases are different 
than aseptic meningitis and appear to be associated with anti-U1RNP Abs. Unfortunately, the 
present study did not clearly indicate which types of central NPSLE that anti-U1RNP Abs 
are most associated with. In accordance with a previous study (27), our data show no 
significant correlation between the presence of serum- or CSF-anti-SSA Abs and central 
NPSLE.  
The presence of ANA in CSF can be explained by three mechanisms: (1) in situ Ab 
production in the CNS, (2) a BBB breach, which would allow Abs to cross a normally 
restricted compartment, and (3) an increased Ab concentration resulting from a reduced CSF 
flow rate. However, our data strongly suggest intrathecal production of anti-U1 RNP Abs, 
because the anti-70K, A, and C indices were not equally elevated, and the anti-U1RNP and 
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70K indices in most patients increased by more than 2.0. Even if a BBB breach or reduced 
flow occurred, it is unlikely that either anti-70K, A, or C Abs penetrated or moved outside 
the CSF. The observation that a different U1-70K peptide recognition pattern by serum and 
CSF anti-70K Abs is evident also suggests intrathecal anti-U1RNP Ab production. 
Remarkably, the autoantigenic 141–164 aa residue for CSF anti-70K Abs in patients with 
central NPSLE was located within the RNA-binding domain (92–202 aa), including T (40) 
and B (41–44) cell major epitopes of human anti-70K Abs. Guldner et al. identified the 
56–195 aa domain as the major antigenic epitope recognized by all tested sera (41). Cram et 
al. reported the 100–156 aa residue as one of the major epitopes in the human 70K protein 
(42). James et al. showed that the basic aa-rich sequences are the early autoantigenic 
determinants of the 70K C-terminus (45). More detailed experiments using a large number of 
CSF samples are necessary to clarify the immunological characteristics of intrathecal 
anti-U1RNP Abs, whereas our results suggest the possibility that an ANA production in CSF 
is stimulated by an antigen-driven mechanism. 
In conclusion, CSF anti-U1RNP Abs, which may be produced in the CNS, are a 
clinically useful indicator for central NPSLE. However, there are some limitations to the 
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present study. First, the usefulness of the anti-U1RNP index is limited to patients with 
NPSLE that have serum anti-U1RNP Abs. Second, RNA-IPP method may be required to 
determine a low anti-U1RNP Ab titer, and third, our results were observed in a small number 
of Japanese patients. A more detailed association of CSF anti-U1RNP Abs with other 
humoral factors or activated neuronal cells in the CNS should be elucidated in a future study. 
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Figure 1. Antinuclear antibody (ANA) detection in sera and CSF by the RNA immunoprecipitation (RNA-IPP) assay. Anti-U1RNP and anti-SS-A/Ro 
(SSA) Abs precipitated U1RNA and SSA-RNA, respectively. CNS manifestations are listed in Table 1 and 2. (A) Serum and CSF samples from 
representative patients with central neuropsychiatric systemic lupus erythematosus (NPSLE). (B) Serum and CSF samples from representative patients 
without central NPSLE.  
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Figure 2. (A) ANA frequency difference in CSF from patients with and without central neuropsychiatric systemic lupus erythematosus (NPSLE). The 
frequency (%) of CSF ANA-positive in serum ANA-positive patients was shown. Anti-U1RNP and SS-A/Ro Abs were determined by RNA-IPP, and 
anti-dsDNA Abs were determined by ELISA. Anti-SSB/La and ribosomal P Abs were not detected in CSF. ANA, antinuclear antibodies; CSF, cerebrospinal 
fluid; IL-6, interleukin-6; Pts, patients; SSA, SS-A/Ro; N.S., not significant. (B) Comparison of the IgG and anti-U1RNP ratios. (C) Correlations between 
the anti-U1RNP index and IL-6, or Qalb. (D) Correlation between the anti-U1RNP ratio and the IgG index. The Pearson’s product moment correlation 
coefficients (r) were calculated in 10 patients with positive CSF anti-U1RNP Abs. IgG ratio = (CSF IgG concentration [mg/dL]/serum IgG concentration 
[mg/dL]), Anti-U1RNP ratio (with a compensation for the difference in serum/CSF dilutions) = (100/5) × (CSF anti-U1RNP Ab arbitrary units/serum 
anti-U1RNP Ab arbitrary units), Qalb (Albumin quotient, normal < 0.0076) = albumin ratio = (CSF albumin concentration [mg/dL]/serum albumin 
concentration [mg/dL]), IgG index = IgG ratio (CSF IgG concentration [mg/dL]/serum IgG concentration [mg/dL])/Qalb, Anti-U1RNP index = (anti-U1RNP 
ratio/IgG ratio) 
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Figure 3. Anti-U1RNP index in eight patients with central neuropsychiatric systemic lupus erythematosus (left) and the anti-70K, A, and C indices in the 
same patients (right) are shown. Serum and cerebrospinal fluid anti-70K, A, and C Ab titers were determined by ELISA using recombinant proteins. The 
patient number corresponds to the Pt number in Table 1. Because an insufficient quantity of sample was obtained from Pt.1, the Pt.1 index was excluded 
from this experiment.  
Anti-U1RNP, 70K, A, and C indices (with a compensation for the serum/CSF dilution difference) = (100/5) × ([CSF Ab arbitrary units/serum Ab arbitrary 
units]/[IgG ratio]) 
Pt, patient; N.S., not significant 
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Figure 4. Autoantigenic peptide residues recognized by serum and 
CSF anti-70K Abs from patients with neuropsychiatric systemic lupus 
erythematosus (NPSLE). The major autoantigenic domains for serum 
and CSF anti-U1-70K Abs were examined using ELISA with 22 
overlapping peptides identical with the partial sequence of U1-70K 
(17–24 amino acids [aa]). Sera and CSF from eight patients with 
central NPSLE were diluted to 100 µg/mL and positivity was 
determined as more than the mean + 2SD of the negative control 
samples obtained from patients without serum and CSF anti-U1RNP 
Abs. The data show the positive frequency of anti-peptide Abs in eight 
serum and CSF samples from CSF anti-U1RNP Ab-positive patients 
with central NPSLE.  
CSF, cerebrospinal fluid   
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Figure 1. Antinuclear antibody (ANA) detection in sera and CSF by the RNA 
immunoprecipitation (RNA-IPP) assay. Anti-U1RNP and anti-SS-A/Ro (SSA) Abs 
precipitated U1RNA and SSA-RNA, respectively. CNS manifestations are listed in Table 1 
and 2. (A) Serum and CSF samples from representative patients with central 
neuropsychiatric systemic lupus erythematosus (NPSLE). (B) Serum and CSF samples from 
representative patients without central NPSLE.  
Pt, patient; T, Total RNAs; S, serum; C, cerebrospinal fluid 
 
Figure 2. (A) ANA frequency difference in CSF from patients with and without central 
neuropsychiatric systemic lupus erythematosus (NPSLE). The frequency (%) of CSF 
ANA-positive in serum ANA-positive patients was shown. Anti-U1RNP and SS-A/Ro Abs 
were determined by RNA-IPP, and anti-dsDNA Abs were determined by ELISA. 
Anti-SSB/La and ribosomal P Abs were not detected in CSF. ANA, antinuclear antibodies; 
CSF, cerebrospinal fluid; IL-6, interleukin-6; Pts, patients; SSA, SS-A/Ro; N.S., not 
significant. (B) Comparison of the IgG and anti-U1RNP ratios. (C) Correlations between the 
Page 82 of 84




anti-U1RNP index and IL-6, or Qalb. (D) Correlation between the anti-U1RNP ratio and the 
IgG index. The Pearson’s product moment correlation coefficients (r) were calculated in 10 
patients with positive CSF anti-U1RNP Abs. 
IgG ratio = (CSF IgG concentration [mg/dL]/serum IgG concentration [mg/dL]) 
Anti-U1RNP ratio (with a compensation for the difference in serum/CSF dilutions) = (100/5) 
× (CSF anti-U1RNP Ab arbitrary units/serum anti-U1RNP Ab arbitrary units) 
Qalb (Albumin quotient, normal < 0.0076) = albumin ratio = (CSF albumin concentration 
[mg/dL]/serum albumin concentration [mg/dL]) 
IgG index = IgG ratio (CSF IgG concentration [mg/dL]/serum IgG concentration 
[mg/dL])/Qalb 
Anti-U1RNP index = (anti-U1RNP ratio/IgG ratio)  
 
Figure 3. Anti-U1RNP index in eight patients with central neuropsychiatric systemic lupus 
erythematosus (left) and the anti-70K, A, and C indices in the same patients (right) are 
shown. Serum and cerebrospinal fluid anti-70K, A, and C Ab titers were determined by 
ELISA using recombinant proteins. The patient number corresponds to the Pt number in 
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Table 1. Because an insufficient quantity of sample was obtained from Pt.1, the Pt.1 index 
was excluded from this experiment.  
Anti-U1RNP, 70K, A, and C indices (with a compensation for the serum/CSF dilution 
difference) = (100/5) × ([CSF Ab arbitrary units/serum Ab arbitrary units]/[IgG ratio]) 
Pt, patient; N.S., not significant 
 
Figure 4. Autoantigenic peptide residues recognized by serum and CSF anti-70K Abs from 
patients with neuropsychiatric systemic lupus erythematosus (NPSLE). The major 
autoantigenic domains for serum and CSF anti-U1-70K Abs were examined using ELISA 
with 22 overlapping peptides identical with the partial sequence of U1-70K (17–24 amino 
acids [aa]). Sera and CSF from eight patients with central NPSLE were diluted to 100 µg/mL 
and positivity was determined as more than the mean + 2SD of the negative control samples 
obtained from patients without serum and CSF anti-U1RNP Abs. The data show the positive 
frequency of anti-peptide Abs in eight serum and CSF samples from CSF anti-U1RNP 
Ab-positive patients with central NPSLE.  
CSF, cerebrospinal fluid   
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